What is pathophysiology of Alzheimer?

Poslušaj to stran.

Kaj je patofiziologija alzheimerjeve bolezni?

Patofiziologija Alzheimerjeve bolezni (AD) je zapleten proces, ki vključuje kopičenje nenormalnih beljakovin, vnetje in nevronske disfunkcije.

Dve glavni značilnosti Alzheimerjeve bolezni sta prisotnost amiloid-beta (Aβ) plošč in nevrofibrilarnih zapletov (NFT) v možganih.

Amyloid- beta plošče nastanejo, ko so fragmenti amiloidnega predhodnega beljakovine (APP) razcepljeni z encimi in tvorijo Aβ peptide.

Ti peptidi se združijo in tvorijo netopljive fibrile, ki se kopičijo zunaj nevronov, kar moti komunikacijo med celicami in vodi do smrti nevronov.

Domneva se, da je kopičenje Aβ plakov eden najzgodnejših dogodkov pri razvoju AD in da prispeva k nevrodegenerativnemu procesu.

Neurofibrilarni zaplet se tvori, ko protein tau postane hiperfosforiliran in tvori nenormalne filamente znotraj nevronov.

Te zapletenosti motijo normalno delovanje mikrotubul, ki so bistvenega pomena za prevoz hranil in drugih materialov znotraj nevrona.

Te zapletenosti sčasoma privedejo do smrti prizadetih nevronov.

Vnetje igra tudi vlogo v patofiziologiji Alzheimerjeve bolezni.

Imunski sistem se odzove na kopičenje Aβ plakov in NFT-jev z sproščanjem pro- vnetnih citokinov, ki lahko poslabšajo poškodbe nevronov.

Poleg tega obstajajo dokazi, da oksidativni stres, mitohondrijska disfunkcija in motena presnova glukoze prispevajo k patofiziologiji Alzheimerjeve bolezni.

Ti dejavniki lahko privedejo do nevronske disfunkcije in smrti, kar še dodatno poslabša proces bolezni.

Na splošno je patofiziologija Alzheimerjeve bolezni zapleten medsebojni vpliv več dejavnikov, ki na koncu vodijo do postopnega upada kognitivnih funkcij in izgube spomina, ki je značilna za bolezen.

Sklicevanja

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

Opozorilo: medicinsko

Ta spletna stran je namenjena samo izobraževalnim in informacijskim namenom in ne pomeni zagotavljanja zdravniških nasvetov ali strokovnih storitev.

Posredovani podatki se ne smejo uporabljati za diagnozo ali zdravljenje zdravstvenega problema ali bolezni, tisti, ki iščejo osebni zdravniški nasvet, pa se morajo posvetovati z licenciranim zdravnikom.

Upoštevajte, da je nevronska mreža, ki ustvarja odgovore na vprašanja, še posebej netočna, ko gre za številčno vsebino, na primer število ljudi, diagnosticiranih z določeno boleznijo.

Vedno poiščite nasvet svojega zdravnika ali drugega usposobljenega zdravstvenega delavca glede zdravstvenega stanja. Nikoli ne prezrite strokovnega zdravniškega nasveta ali odložite iskanja zaradi nečesa, kar ste prebrali na tej spletni strani. Če menite, da imate zdravniški nujen primer, pokličite 911 ali takoj pojdite v najbližjo urgenco. Ta spletna stran ali njena uporaba ne ustvarja nobenega odnosa med zdravnikom in bolnikom. Niti BioMedLib niti njeni zaposleni, niti kateri koli sodelavec na tej spletni strani ne daje nobenih izjav, izrecnih ali implicitnih, v zvezi z informacijami, ki so na voljo na tej spletni strani ali z njeno uporabo.

Opozorilo: avtorske pravice

Zakon o avtorskih pravicah za digitalno tisočletje iz leta 1998, 17 U.S.C. § 512 (DMCA) zagotavlja sredstva za lastnike avtorskih pravic, ki menijo, da material, ki se pojavlja na internetu, krši njihove pravice v skladu z ameriškim zakonom o avtorskih pravicah.

Če v dobri veri menite, da katera koli vsebina ali material, ki je na voljo v povezavi z našo spletno stranjo ali storitvami, krši vaše avtorske pravice, nam lahko (ali vašemu zastopniku) pošljete obvestilo, v katerem zahtevate odstranitev vsebine ali materiala ali blokiranje dostopa do njega.

Obvestila je treba poslati v pisni obliki po e-pošti (za e-poštni naslov glejte razdelek "Kontakt").

DMCA zahteva, da vaše obvestilo o domnevni kršitvi avtorskih pravic vključuje naslednje informacije: (1) opis avtorsko varovanega dela, ki je predmet domnevne kršitve; (2) opis domnevne vsebine, ki krši avtorske pravice, in informacije, ki so zadostne, da nam omogočijo iskanje vsebine; (3) kontaktne informacije za vas, vključno z vašim naslovom, telefonsko številko in e-poštnim naslovom; (4) izjavo, da imate v dobri veri prepričanje, da vsebina na način, o katerem se pritožujete, ni odobrena s strani imetnika avtorskih pravic ali njegovega zastopnika ali z delovanjem katerega koli zakona;

(5) vašo izjavo, podpisano pod kaznijo krivokletstva, da so informacije v uradnem obvestilu točne in da imate pooblastilo za uveljavljanje avtorskih pravic, ki naj bi bile kršene;

in (6) fizični ali elektronski podpis imetnika avtorskih pravic ali osebe, pooblaščene, da deluje v imenu imetnika avtorskih pravic.

Če ne vključite vseh zgornjih informacij, se lahko obravnava vaše pritožbe odloži.

Kontaktni podatki

Prosimo, pošljite nam e-pošto s kakršnim koli vprašanjem / predlogom.

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.